Quest Diagnostics Inc

Quest Diagnostics shares soar with a new dividend, 14%+ CAGR and AI‑driven labs—learn how the company’s tech, margin growth and payer strategy power investor returns.

Quest Diagnostics’ $500 M 5% senior note issuance gives it the capital to boost high‑margin molecular tests, automate labs, and expand patient access while keeping debt‑service risk low.

Quest Diagnostics raises $500 M with 5% senior notes due 2036 to fund growth, refinance debt and boost shareholder value.

Quest Diagnostics’ latest earnings reveal a shift toward high‑margin, tech‑enabled testing—underlying growth, cost‑efficiency, and regulatory challenges that could reshape its valuation and investor outlook.

Quest Diagnostics Q1 2026: revenue & earnings rise, cost‑saving “Invigorate” fuels profitability, AI‑driven diagnostics & a Michigan acquisition boost growth.

Quest Diagnostics reports a strong Q1 2026, boosting revenue and EPS by 9 % and 13 % YoY, driven by AI diagnostics, Project Nova efficiency gains, and dialysis testing growth.

Quest Diagnostics Q4 2026 earnings forecast: steady revenue growth, rising EPS, digital expansion, and strategic partnerships signal resilient profit momentum.

Quest Diagnostics 2026 Annual Meeting: governance changes, advanced diagnostics, and data‑driven growth in a shifting reimbursement landscape.

Quest Diagnostics adds former Walgreens CEO Timothy Wentworth to its board, signaling a pharmacy‑benefit push that could boost diagnostics revenue and market reach while navigating regulatory and integration risks.

Quest Diagnostics launches an AI‑powered companion in MyQuest, boosting patient engagement and revenue while improving care quality and operating margins.